A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
PHASE1
This is a study to compare the similarity in Pharmacokinetics (PK) profile ...
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
PHASE2
This phase II trial studies how well TPIV100 and sargramostim work in treat...
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
PHASE3
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab...
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
PHASE3
To compare the efficacy and safety of PERT-IJS (Proposed biosimilar Pertuzu...
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
PHASE2
This phase II trial studies the immunologic response and side effects of us...
Status
Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
PHASE1
This randomized phase I/II trial studies the side effects of vaccine therap...
Status
Completed
Location
Fred Hutch/University of Washington Cancer Consortium